PDS Biotechnology Corp Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PDS Biotechnology Corp (PDSB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.16 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.16M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.65M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.67M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.70M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $4.16M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $3.65M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $4.67M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $2.70M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $1.37M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $1.69M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $2.15M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 | $1.85M 10-K · filed 2019-02-21 |
| 2017-12-31 | $1.61M 10-K · filed 2019-02-21 | |
| 2016-12-31 | $1.42M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $669.01K 10-K · filed 2017-03-02 | |
| 2014-12-31 | $309.89K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |